Clinical Trials Logo

Obesity clinical trials

View clinical trials related to Obesity.

Filter by:

NCT ID: NCT06391320 Recruiting - Obesity Clinical Trials

Obesity Queue Database

Start date: September 1, 2023
Phase:
Study type: Observational

To establish an obesity specific disease cohort database and form a special disease cohort, so as to provide guarantee for carrying out high-quality real-world clinical research and clinical research.

NCT ID: NCT06390904 Recruiting - Obesity Clinical Trials

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients

Start date: July 13, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

To investigate the efficacy of Gonadotropin-releasing Hormone Agonist (GnRHa) plus letrozole in obese progestin-insensitive atypical endometrial hyperplasia (EAH) patients.

NCT ID: NCT06390189 Not yet recruiting - Obesity Clinical Trials

Inflammatory Resolution in Cardiometabolic Health and Disease

RESOLVE AU
Start date: May 1, 2024
Phase:
Study type: Observational

The specific aim of this study is to determine molecular pathways that differentiate metabolically healthy vs unhealthy human phenotypes, and to investigate the therapeutic potential of pro-resolving lipids. Investigators will recruit volunteers that are metabolically healthy or unhealthy that fall within three BMI ranges: lean (18.-24.9 kg/m2), overweight (25.0-29.9 kg/m2) and obese (>30.0 kg/m2). Investigators hypothesize that metabolically healthy individuals have a superior endogenous capacity to regulate an inflammatory/resolving response.

NCT ID: NCT06388187 Not yet recruiting - Obesity Clinical Trials

A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

Start date: June 24, 2024
Phase: Phase 3
Study type: Interventional

This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will either get CagriSema or dummy medicine and which treatment participant get is decided by chance. The study will last for about 1½ years for each participant.

NCT ID: NCT06387719 Recruiting - Obesity Clinical Trials

Precursors of Binge Eating Disorder in a Clinical Sample of Adolescents With Obesity

PREC-BED
Start date: July 21, 2023
Phase:
Study type: Observational [Patient Registry]

BACKGROUND: Binge eating disorder (BED) is the worldwide most-prevalent eating disorder. It is associated with psychiatric comorbidities and obesity, a high impact in life functioning, and high morbidity and mortality. First symptoms appear frequently in youths, who most commonly present incomplete (subthreshold) criteria for BED (precursor forms, PREC-BED). While some subjects will evolve from PREC-BED to BED, there is no gold standard to identify the clinical evolution. Information from prior studies suggest early alterations in reward and inhibitory brain circuits in PREC-BED may predict increased vulnerability or resilience to develop BED. Tools based on MRI brain connectivity analyses (MRI-BC), built on robust and interpretable connectivity whole-brain models, have proven successful in diagnostic classification and predicting certain clinical outcomes. OBJECTIVES: To study MRI-BC diagnostic markers of PREC-BED and to explore prognosis at 1 year of follow-up in a sample of adolescents with obesity (12-17 years old). METHODS: A) Transversal analytical design: 3-group (n=34 per group) comparison of neuroimaging (MRI-BC), neurocognitive and clinical markers in adolescents with obesity and i) BED, ii) PREC-BED, iii) no BED nor PREC-BED (Healthy group, HC). B) Longitudinal analytical design, pilot, exploratory: adolescents with PREC-BED will be evaluated in clinical and neurocognitive variables at 1 year. Baseline brain neuroimaging variables (alone and in combination with clinical and neurocognitive variables) will be analyzed as predictors of clinical prognosis, including conversion to BED.

NCT ID: NCT06385860 Not yet recruiting - Obesity Clinical Trials

Prediction Model for Early Biliary Stasis After Bariatric Surgery

PM-EBS-BS
Start date: July 2024
Phase:
Study type: Observational

Developing and validating a predictive model to estimate the risk of early biliary stasis following bariatric surgery

NCT ID: NCT06384313 Not yet recruiting - Obesity Clinical Trials

Butyrate-enriched Triglyceride and Diabetes Prevention

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

A body of animal studies as well as observational studies in humans demonstrated that butyrate is one SCFA that has pronounced positive effects on body weight control, inflammation, and insulin resistance. Even though the SCFA hexanoate is less researched, it has been shown to be involved in anti-inflammatory processes. Of note, acute human studies showed that fibre-induced metabolic improvements are linked to higher SCFA levels in the systemic circulation. It has been shown that a butyrate/hexanoate-enriched triglyceride oil enhanced systemic butyrate and hexanoate concentrations for a prolonged time. Yet, it remains to be determined whether a chronic increase in circulating butyrate and hexanoate concentrations translate into long-term benefits. In this study it is hypothesized that a chronic increase of butyrate/hexanoate in the circulation may improve host metabolism and metabolic health by improving adipose tissue function, reducing systemic lipid overflow and inflammation thereby increasing peripheral insulin sensitivity in individual with overweight/obesity and prediabetes.

NCT ID: NCT06383390 Recruiting - Clinical trials for Overweight and Obesity

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)

Start date: April 30, 2024
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.

NCT ID: NCT06382506 Completed - Obesity Clinical Trials

The Effect of Hazelnut Flour on Blood Glucose

Hazelnut
Start date: March 21, 2024
Phase: N/A
Study type: Interventional

One of the factors affecting human health is nutrition. The effects of foods on blood glucose are still under investigation. The Glycemic Index (GI), which is associated with many diseases today, is a value that measures the rate at which carbohydrate-containing foods raise blood glucose. It is thought that the loaves of bread produced will be a product with low GI value and can be consumed by celiacs and diabetics. It is aimed to investigate the effect of adding different amounts of hazelnut flour to bread recipes using gluten-free corn flour on blood glucose.

NCT ID: NCT06382480 Recruiting - Obesity Clinical Trials

PROTeIn-rich Meals to Control Glucose

PROTIME
Start date: April 12, 2024
Phase: N/A
Study type: Interventional

The overall aim is to identify the dietary pattern for prevention and treatment of type 2 diabetes. The specific aim of this pilot project is to compare effects of two diets with different diurnal distribution of carbohydrates and protein on the glucose metabolism in subjects with prediabetes and type 2 diabetes and its effects on inflammatory status.